Relationship Between Clinical Outcome Measures and Parent Proxy Reports of Health-Related Quality of Life in Ambulatory Children With Duchenne Muscular Dystrophy

In Duchenne muscular dystrophy, data directly linking changes in clinical outcome measures to patient-perceived well-being are lacking. This study evaluated the relationship between clinical outcome measures used in clinical trials of ambulatory Duchenne muscular dystrophy (Vignos functional grade, quantitative knee extension strength, timed functional performance measures, and gait velocity) and 2 health-related quality of life measures—the Pediatric Outcomes Data Collection Instrument and Pediatric Quality of Life Inventory—in 52 ambulatory Duchenne muscular dystrophy subjects and 36 controls. Those with the disease showed significant decrements in parent proxy-reported health-related quality of life measures versus controls across all domains. The Pediatric Outcomes Data Collection Instrument transfers/basic mobility and sports/ physical function and the Pediatric Quality of Life Inventory physical functioning domains had significant associations with age (and hence disease progression) and traditional clinical outcome measures employed in clinical trials of ambulatory boys with Duchenne muscular dystrophy. Selected domains of the Pediatric Outcomes Data Collection Instrument and generic Pediatric Quality of Life Inventory are potential patient-reported outcome measures for clinical trials in ambulatory individuals with the disease.

[1]  Jay J. Han,et al.  The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.

[2]  J. Varni,et al.  The PedsQL™ in Pediatric Patients with Duchenne Muscular Dystrophy: Feasibility, Reliability, and Validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales , 2010, Journal of clinical neuromuscular disease.

[3]  J. Varni,et al.  The PedsQL™ in pediatric patients with Spinal Muscular Atrophy: Feasibility, reliability, and validity of the Pediatric Quality of Life Inventory™ Generic Core Scales and Neuromuscular Module , 2009, Neuromuscular Disorders.

[4]  A. Riley,et al.  Development of Items Designed to Evaluate Activity Performance and Participation in Children and Adolescents with Spinal Cord Injury , 2009, International journal of pediatrics.

[5]  J. Varni,et al.  The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents. , 2009, Pediatric clinics of North America.

[6]  J. Varni,et al.  The PedsQL™ 4.0 Generic Core Scales Young Adult Version , 2009, Journal of health psychology.

[7]  Anna Carla Turconi,et al.  Gait pattern in Duchenne muscular dystrophy. , 2009, Gait & posture.

[8]  D. Dewey,et al.  Parental stress and quality of life in children with neuromuscular disease. , 2008, Pediatric neurology.

[9]  A. Pestronk,et al.  A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy , 2008, Annals of neurology.

[10]  G. Gorton,et al.  Pediatric Outcomes Data Collection Instrument Scores in Ambulatory Children With Cerebral Palsy: An Analysis by Age Groups and Severity Level , 2008, Journal of pediatric orthopedics.

[11]  Liz J. Jansky,et al.  Using Focus Groups To Inform the Neuro‐QOL Measurement Tool: Exploring Patient‐Centered, Health‐Related Quality of Life Concepts Across Neurological Conditions , 2007, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[12]  M. Sampaolesi,et al.  New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. , 2007, Trends in molecular medicine.

[13]  N. Goemans,et al.  CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy. , 2007, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[14]  J. Fries,et al.  The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH Roadmap Cooperative Group During its First Two Years , 2007, Medical care.

[15]  M. Rose,et al.  Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL) , 2007, Neurology.

[16]  B. Wong,et al.  A Randomized, Placebo-Controlled Trial of Creatine in Children With Spinal Muscular Atrophy , 2007 .

[17]  K. Waters,et al.  Outcome of noninvasive ventilation in children with neuromuscular disease , 2007, Neurology.

[18]  Tasha M Burwinkle,et al.  How young can children reliably and validly self-report their health-related quality of life?: An analysis of 8,591 children across age subgroups with the PedsQL™ 4.0 Generic Core Scales , 2007, Health and quality of life outcomes.

[19]  J. Mendell,et al.  Challenges in drug development for muscle disease: A stakeholders' meeting , 2007, Muscle & nerve.

[20]  R. McCarter,et al.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy , 2007, Muscle & nerve.

[21]  K. Hickey,et al.  Impact of Spinal Cord Dysfunction and Obesity on the Health-Related Quality of Life of Children and Adolescents , 2007, The journal of spinal cord medicine.

[22]  A. Pestronk,et al.  CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy , 2005, Annals of neurology.

[23]  Richard C Gershon,et al.  Computer adaptive testing , 1994 .

[24]  G. Chard.  International Classification of Functioning, Disability and Health , 2004 .

[25]  Michael Seid,et al.  The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. , 2003, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.

[26]  N. Leidy,et al.  Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  L. Hynan,et al.  Reliability of 4 outcome measures in pediatric spinal muscular atrophy. , 2003, Archives of neurology.

[28]  D. A. Cioffi,et al.  The American Academy of Orthopaedic Surgeons Outcomes Instruments: Normative Values from the General Population , 2002, The Journal of bone and joint surgery. American volume.

[29]  J. Varni,et al.  The PedsQL 4.0 Generic Core Scales: sensitivity, responsiveness, and impact on clinical decision-making. , 2002, Journal of behavioral medicine.

[30]  R. Haynes,et al.  The Pediatric Orthopaedic Society of North America Pediatric Orthopaedic Functional Health Questionnaire: An Analysis of Normals , 2001, Journal of pediatric orthopedics.

[31]  Michael Seid,et al.  PedsQL™ 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in Healthy and Patient Populations , 2001, Medical care.

[32]  James G Wright,et al.  Comparison of Three Outcomes Instruments in Children , 2001, Journal of pediatric orthopedics.

[33]  D. Escolar,et al.  Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children , 2001, Muscle & nerve.

[34]  P. Raina,et al.  Validation of a model of gross motor function for children with cerebral palsy. , 2000, Physical therapy.

[35]  J. Varni,et al.  The PedsQL: measurement model for the pediatric quality of life inventory. , 1999, Medical care.

[36]  M H Liang,et al.  The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America. , 1998, Journal of pediatric orthopedics.

[37]  R. Abresch,et al.  Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[38]  R. Abresch,et al.  Profiles of neuromuscular diseases. Duchenne muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[39]  A. Pestronk,et al.  Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy , 1991, Neurology.

[40]  A. Pestronk,et al.  A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. , 1991, Archives of neurology.

[41]  A. Pestronk,et al.  Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. , 1991, Archives of neurology.

[42]  J. Miller,et al.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. , 1989, The New England journal of medicine.

[43]  J. Miller,et al.  Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. , 1987, Archives of neurology.

[44]  V. Dubowitz,et al.  Intellect and Behaviour in Duchenne Muscular Dystrophy , 1981, Developmental medicine and child neurology.

[45]  M. Brooke,et al.  Clinical trial in duchenne dystrophy. I. The design of the protocol , 1981, Muscle & nerve.

[46]  R. Olshen,et al.  The Pathomechanics of Gait in Duchenne Muscular Dystrophy , 1981, Developmental medicine and child neurology.

[47]  P. Vignos,et al.  Maintenance of ambulation in childhood muscular dystrophy. , 1960, Journal of chronic diseases.

[48]  Vignos Pj,et al.  A study of contractures in muscular dystrophy. , 1959 .

[49]  P. Vignos,et al.  A study of contractures in muscular dystrophy. , 1959, Archives of physical medicine and rehabilitation.